Gu Xianhua, Shen Honghong, Xiang Zheng, Li Xinwei, Zhang Yue, Zhang Rong, Su Fang, Wang Zishu
Department of Gynecology Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of China.
Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of China.
Pharmgenomics Pers Med. 2023 Jun 1;16:519-535. doi: 10.2147/PGPM.S411199. eCollection 2023.
, an orphan G protein-coupled receptor (GPCR), is essential for the progression of gastrointestinal cancers. However, it is still unclear how affects tumor immunity and patient prognosis in gastric cancer (GC).
The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were searched in this investigation to assess the expression patterns of in GC tissues and normal gastric mucosa. The findings were further verified using immunohistochemical tests and quantitative Real-Time Polymerase Chain Reaction (qRT-PCR). The Kaplan-Meier method, univariate logistic regression, and Cox regression were then used to investigate the relationship between and clinical traits. Additionally, the potential correlation between , immune checkpoint genes, and immune cell infiltration levels was investigated.
As per the research findings, GC tissues had higher levels of than normal tissues. Additionally, individuals with high expression of had a worse 10-year overall survival (OS), in contrast with those having a low expression of ( < 0.001). The OS of GC can be predicted using a validated nomogram model. The expression of demonstrated a negative correlation with CD8+ T cells. When compared to the low-expression group of , Tumor Immune Dysfunction and Exclusion (TIDE) analysis demonstrated that the high-expression group had a considerably higher risk of immune evasion. A remarkable difference (variation) was observed in the levels of expression across both groups, ie, low and high-risk groups, as determined by the immune phenomenon scores (IPS) immunotherapy assessment.
By examining from various biological perspectives, it was determined that can act as a predictive biomarker for poor patient prognosis in GC. Additionally, it was observed that is capable of suppressing the proliferation of CD8+ T cells and facilitating immune evasion.
作为一种孤儿G蛋白偶联受体(GPCR),对于胃肠道癌症的进展至关重要。然而,其如何影响胃癌(GC)的肿瘤免疫和患者预后仍不清楚。
本研究检索了癌症基因组图谱(TCGA)和基因表达综合数据库(GEO),以评估在GC组织和正常胃黏膜中的表达模式。研究结果通过免疫组织化学检测和定量实时聚合酶链反应(qRT-PCR)进一步验证。然后使用Kaplan-Meier法、单因素逻辑回归和Cox回归研究与临床特征之间的关系。此外,还研究了与免疫检查点基因和免疫细胞浸润水平之间的潜在相关性。
根据研究结果,GC组织中的水平高于正常组织。此外,高表达的个体10年总生存率(OS)较差,而低表达的个体则相反(<0.001)。可以使用经过验证的列线图模型预测GC的OS。的表达与CD8 + T细胞呈负相关。与低表达组相比,肿瘤免疫功能障碍和排除(TIDE)分析表明,高表达组的免疫逃逸风险明显更高。根据免疫现象评分(IPS)免疫治疗评估,在低风险和高风险两组的表达水平上观察到显著差异。
通过从各种生物学角度研究,确定可以作为GC患者预后不良的预测生物标志物。此外,还观察到能够抑制CD8 + T细胞的增殖并促进免疫逃逸。